Document Classification

Section Type: RESULTS

Text: Compared with 1802 patients allocated to receive heparin plus a GPI, 1800 patients allocated to bivalirudin monotherapy had lower rates of all-cause mortality (59 % vs 77 %, difference -19 % [-35 to -02], HR 075 [058-097] ; p = 003), cardiac mortality (29 % vs 51 %, -22 % [-35 to -09], 056 [040-080] ; p = 0001), reinfarction (62 % vs 82 %, -19 % [-37 to -02], 076 [059-099] ; p = 004), and major bleeding not related to bypass graft surgery (69 % vs 105 %, -36 % [-55 to -17], 064 [051-080] ; p = 00001) at 3 years, with no significant differences in ischaemia-driven target vessel revascularisation, stent thrombosis, or composite adverse events.